Efficient Modification of the CCR5 Locus in Primary Human T Cells With megaTAL Nuclease Establishes HIV-1 Resistance

Molecular Therapy Nucleic Acids

Volumn 5, Issue , 2016, Pages e352-

  Romano Ibarra, Guillermo S ^a   Paul, Biswajit ^b   Sather, Blythe D ^a   Younan, Patrick M ^b   Sommer, Karen ^a   Kowalski, John P ^b   Hale, Malika ^a   Stoddard, Barry ^b   Jarjour, Jordan ^c   Astrakhan, Alexander ^c   Kiem, Hans Peter ^b,d   Rawlings, David J ^a,d  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b USA   (United States)

^c BLUEBIRD BIO   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

CCR5; gene editing; Gene therapy; HIV; megaTAL

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MEGATAL NUCLEASE; MESSENGER RNA; NUCLEASE; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELL TRANSPLANTATION; CONTROLLED STUDY; DNA MODIFICATION; ENGRAFTMENT; GENE EXPRESSION; GENE LOCUS; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS ENTRY; VIRUS IMMUNITY; ANTIVIRAL RESISTANCE; DRUG TARGETING; GENE DISRUPTION; GENETIC ENGINEERING; GENETIC TRANSFECTION; NORMAL HUMAN; PRIMARY CELL; PROTEIN MODIFICATION;

EID: 85015150527     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2016.56     Document Type: Article

References (52)

1. 1 Robbins, RN, Spector, AY, Mellins, CA, Remien, RH, Optimizing ART adherence: update for HIV treatment and prevention. Curr HIV/AIDS Rep 11 (2014), 423–433.
2. 2 Detels, R, Muñoz, A, McFarlane, G, Kingsley, LA, Margolick, JB, Giorgi, J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 280 (1998), 1497–1503.
3. 3 Pérez-Hoyos, S, del Amo, J, Muga, R, del Romero, J, García de Olalla, P, Guerrero, R, et al., GEMES (Spanish Multicenter Study Group of Seroconverters), Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS 17 (2003), 353–359.
4. 4 Siliciano, JD, Siliciano, RF, Recent trends in HIV-1 drug resistance. Curr Opin Virol 3 (2013), 487–494.
5. 5 Deeks, SG, HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 62 (2011), 141–155.
6. 6 Dean, M, Carrington, M, Winkler, C, Huttley, GA, Smith, MW, Allikmets, R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273 (1996), 1856–1862.
7. 7 Dragic, T, Litwin, V, Allaway, GP, Martin, SR, Huang, Y, Nagashima, KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381 (1996), 667–673.
8. 8 Liu, R, Paxton, WA, Choe, S, Ceradini, D, Martin, SR, Horuk, R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86 (1996), 367–377.
9. 9 Glass, W.G., McDermott, D.H., Lim, J.K., Lekhong, S., Yu, S.F., Frank, W.A., Pape, J., Cheshier, R.C., Murphy, P.M., CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203 (2006), 35–40.
10. 10 Galvani, AP, Novembre, J, The evolutionary history of the CCR5-Delta32 HIV-resistance mutation. Microbes Infect 7 (2005), 302–309.
11. 11 Allers, K, Hütter, G, Hofmann, J, Loddenkemper, C, Rieger, K, Thiel, E, et al. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood 117 (2011), 2791–2799.
12. 12 Hütter, G, Nowak, D, Mossner, M, Ganepola, S, Müssig, A, Allers, K, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360 (2009), 692–698.
13. 13 Henrich, TJ, Hanhauser, E, Marty, FM, Sirignano, MN, Keating, S, Lee, TH, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med 161 (2014), 319–327.
14. 14 Henrich, TJ, Hu, Z, Li, JZ, Sciaranghella, G, Busch, MP, Keating, SM, et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 207 (2013), 1694–1702.
15. 15 Cannon, P, June, C, Chemokine receptor 5 knockout strategies. Curr Opin HIV AIDS 6 (2011), 74–79.
16. 16 Kiem, HP, Jerome, KR, Deeks, SG, McCune, JM, Hematopoietic-stem-cell-based gene therapy for HIV disease. Cell Stem Cell 10 (2012), 137–147.
17. 17 Li, L, Krymskaya, L, Wang, J, Henley, J, Rao, A, Cao, LF, et al. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther 21 (2013), 1259–1269.
18. 18 Didigu, CA, Wilen, CB, Wang, J, Duong, J, Secreto, AJ, Danet-Desnoyers, GA, et al. Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. Blood 123 (2014), 61–69.
19. 19 Holt, N, Wang, J, Kim, K, Friedman, G, Wang, X, Taupin, V, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28 (2010), 839–847.
20. 20 Maier, DA, Brennan, AL, Jiang, S, Binder-Scholl, GK, Lee, G, Plesa, G, et al. Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. Hum Gene Ther 24 (2013), 245–258.
21. 21 Tebas, P, Stein, D, Tang, WW, Frank, I, Wang, SQ, Lee, G, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370 (2014), 901–910.
22. 22 Urnov, FD, Miller, JC, Lee, YL, Beausejour, CM, Rock, JM, Augustus, S, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435 (2005), 646–651.
23. 23 Yi, G, Choi, JG, Bharaj, P, Abraham, S, Dang, Y, Kafri, T, et al. CCR5 gene editing of resting CD4(+) T cells by transient ZFN expression from HIV envelope pseudotyped nonintegrating lentivirus confers HIV-1 resistance in humanized mice. Mol Ther Nucleic Acids, 3, 2014, e198.
24. 24 Boissel, S, Jarjour, J, Astrakhan, A, Adey, A, Gouble, A, Duchateau, P, et al. megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering. Nucleic Acids Res 42 (2014), 2591–2601.
25. 25 Sather, BD, Romano Ibarra, GS, Sommer, K, Curinga, G, Hale, M, Khan, IF, et al. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med, 7, 2015, 307ra156.
26. 26 Jarjour, J, West-Foyle, H, Certo, MT, Hubert, CG, Doyle, L, Getz, MM, et al. High-resolution profiling of homing endonuclease binding and catalytic specificity using yeast surface display. Nucleic Acids Res 37 (2009), 6871–6880.
27. 27 Wang, Y, Khan, IF, Boissel, S, Jarjour, J, Pangallo, J, Thyme, S, et al. Progressive engineering of a homing endonuclease genome editing reagent for the murine X-linked immunodeficiency locus. Nucleic Acids Res 42 (2014), 6463–6475.
28. 28 Mörner, A, Björndal, A, Albert, J, Kewalramani, VN, Littman, DR, Inoue, R, et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 73 (1999), 2343–2349.
29. 29 Certo, MT, Gwiazda, KS, Kuhar, R, Sather, B, Curinga, G, Mandt, T, et al. Coupling endonucleases with DNA end-processing enzymes to drive gene disruption. Nat Methods 9 (2012), 973–975.
30. 30 Gornalusse, GG, Mummidi, S, Gaitan, AA, Jimenez, F, Ramsuran, V, Picton, A, et al. Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor. Proc Natl Acad Sci USA 112 (2015), E4762–E4771.
31. 31 Thyme, SB, Jarjour, J, Takeuchi, R, Havranek, JJ, Ashworth, J, Scharenberg, AM, et al. Exploitation of binding energy for catalysis and design. Nature 461 (2009), 1300–1304.
32. 32 Perez, EE, Wang, J, Miller, JC, Jouvenot, Y, Kim, KA, Liu, O, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26 (2008), 808–816.
33. 33 Carrington, M, Dean, M, Martin, MP, O'Brien, SJ, Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. Hum Mol Genet 8 (1999), 1939–1945.
34. 34 Osborn, MJ, Webber, BR, Knipping, F, Lonetree, CL, Tennis, N, DeFeo, AP, et al. Evaluation of TCR gene editing achieved by TALENs, CRISPR/Cas9, and megaTAL nucleases. Mol Ther 24 (2016), 570–581.
35. 35 Alba, R, Bosch, A, Chillon, M, Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 12:suppl. 1 (2005), S18–S27.
36. 36 Stilwell, JL, Samulski, RJ, Role of viral vectors and virion shells in cellular gene expression. Mol Ther 9 (2004), 337–346.
37. 37 Seiler, MP, Cerullo, V, Lee, B, Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects. Curr Gene Ther 7 (2007), 297–305.
38. 38 Almåsbak, H, Rian, E, Hoel, HJ, Pulè, M, Wälchli, S, Kvalheim, G, et al. Transiently redirected T cells for adoptive transfer. Cytotherapy 13 (2011), 629–640.
39. 39 Kordelas, L, Verheyen, J, Beelen, DW, Horn, PA, Heinold, A, Kaiser, R, et al., Essen HIV AlloSCT Group, Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med 371 (2014), 880–882.
40. 40 Hildinger, M, Dittmar, MT, Schult-Dietrich, P, Fehse, B, Schnierle, BS, Thaler, S, et al. Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol 75 (2001), 3038–3042.
41. 41 Petit, N, Dorgham, K, Levacher, B, Burlion, A, Gorochov, G, Marodon, G, Targeting both viral and host determinants of human immunodeficiency virus entry, using a new lentiviral vector coexpressing the T20 fusion inhibitor and a selective CCL5 intrakine. Hum Gene Ther Methods 25 (2014), 232–240.
42. 42 Perez, EE, Riley, JL, Carroll, RG, von Laer, D, June, CH, Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor. Clin Immunol 115 (2005), 26–32.
43. 43 Egelhofer, M, Brandenburg, G, Martinius, H, Schult-Dietrich, P, Melikyan, G, Kunert, R, et al. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol 78 (2004), 568–575.
44. 44 Wolstein, O, Boyd, M, Millington, M, Impey, H, Boyer, J, Howe, A, et al. Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor. Mol Ther Methods Clin Dev, 1, 2014, 11.
45. 45 Liu, L, Patel, B, Ghanem, MH, Bundoc, V, Zheng, Z, Morgan, RA, et al. Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity. J Virol 89 (2015), 6685–6694.
46. 46 Sahu, GK, Sango, K, Selliah, N, Ma, Q, Skowron, G, Junghans, RP, Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology 446 (2013), 268–275.
47. 47 Bitton, N, Verrier, F, Debré, P, Gorochov, G, Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120. Eur J Immunol 28 (1998), 4177–4187.
48. 48 Romeo, C, Seed, B, Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 64 (1991), 1037–1046.
49. 49 Gartner, S, Markovits, P, Markovitz, DM, Kaplan, MH, Gallo, RC, Popovic, M, The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233 (1986), 215–219.
50. 50 Popovic, M, Gartner, S, Read-Connole, E, Beaver, B, Reitz, M, Cell Tropism and expression of HIV-1 isolates in natural targets. Girard, M, Valette, L, (eds.) Retroviruses of Human AIDS and Related Animal Diseases, 1988, Fondation Marcel Merieux, Lyon, 275 Pasteur Vaccins (Marnes-la-Coquette): Lyon; Marnes-la-Coquette.
51. 51 Yuan, J, Wang, J, Crain, K, Fearns, C, Kim, KA, Hua, KL, Gregory, PD, Holmes, MC, Torbett, BE, Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment. Mol. Ther. 20:4 (2002), 849–859.
52. 52 Blanpain, C, Lee, B, Vakili, J, Doranz, BJ, Govaerts, C, Migeotte, I, et al. Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity. J Biol Chem 274 (1999), 18902–18908.